| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Tioxazafen targets plant-parasitic nematodes, including lesion, root-knot, cyst, reniform, and needle nematodes. Its mechanism of action as a nematicide is not fully elucidated but is believed to involve disruption of nematode nervous system or metabolic function. As a systemic seed treatment, the compound is absorbed by the plant and distributed throughout the tissues, providing protection against nematode infection. Its broad-spectrum activity makes it effective against multiple nematode species that affect major crops.
|
|---|---|
| ln Vitro |
As effective as commercial standard nematicidal active components, thiazofen directly kills nematodes by acting on RKN (meloidogyne incognita) and SCN (glycine). Tioxazafen exhibits exceptional efficacy against lesion, root-knot, and needle nematodes in maize; reniform nematodes and root-knot nematodes in cotton; and cyst, root-knot, and reniform nematodes in soybeans [1].
Tioxazafen exhibits potent in vitro nematicidal activity against a range of plant-parasitic nematode species. Its activity is assessed in laboratory assays where nematodes are exposed to varying concentrations of the compound, and mortality or mobility is measured. The compound's systemic activity is evaluated in plant-based assays, where nematode infection and reproduction are assessed in treated plants. These in vitro activities confirm its efficacy as a nematicide. |
| ln Vivo |
Tioxazafen is used in vivo as a seed treatment for crops such as maize, soybeans, and cotton. The compound is applied to seeds before planting, and it is absorbed by the developing plant, providing systemic protection against nematode infection. Field trials have demonstrated that tioxazafen provides consistent broad-spectrum control of nematodes and improves crop yield. Its efficacy against multiple nematode species makes it a valuable tool for agricultural pest management.
|
| Enzyme Assay |
In vitro nematicidal assays for Tioxazafen involve measuring its activity against plant-parasitic nematodes. Nematodes are extracted from soil or cultured in vitro and exposed to varying concentrations of the compound. Nematode mortality or mobility is assessed after a defined exposure period. The EC50 or LC50 is determined from dose-response curves. These assays confirm the compound's nematicidal activity.
|
| Cell Assay |
In vitro cellular assays for Tioxazafen are not typically performed, as the compound is a nematicide rather than a therapeutic agent. However, its effects on nematode cells can be studied using nematode culture systems. Nematode viability, motility, and reproduction are assessed in the presence of the compound. These assays are used in agricultural research.
|
| Animal Protocol |
In vivo animal experiments with Tioxazafen are not typically performed, as the compound is an agricultural nematicide rather than a therapeutic agent. However, its efficacy and safety are evaluated in field trials and greenhouse studies. Crop plants are treated with the compound, and nematode infection, plant growth, and yield are assessed. These studies are important for agricultural applications.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Tioxazafen are not relevant in the context of human therapeutics, as the compound is an agricultural nematicide. It is applied as a seed treatment and is absorbed by plants. Its environmental fate and degradation are studied in agricultural research. The compound has a molecular weight of 228.27 and is available in high purity for research applications.
|
| Toxicity/Toxicokinetics |
Tioxazafen is considered to have low toxicity to mammals, as it is used as a seed treatment at low application rates. However, comprehensive toxicological evaluations for human health are not extensively published. The compound is intended for agricultural use only and is not approved for human therapeutic use. Standard safety precautions should be followed when handling this compound.
|
| References |
[1]. Urszula Slomczynska, et al. Tioxazafen: A New Broad-Spectrum Seed Treatment Nematicide. Discovery and Synthesis of Crop Protection Products. 2015, Chapter 10: pp 129-147.
|
| Additional Infomation |
Tioxazafen is a 1,2,4-oxadiazole compound in which the hydrogen atoms at positions 3 and 5 are replaced by phenyl and thiophene-2-yl groups, respectively. It is a broad-spectrum nematicide seed treatment agent, serving as both a nematicide and an agrochemical. It belongs to the thiophene class of compounds and is also a 1,2,4-oxadiazole compound.
Tioxazafen is a disubstituted 1,2,4-oxadiazole compound that functions as a broad-spectrum, systemic seed treatment nematicide. It is also known as 3-phenyl-5-(2-thienyl)-1,2,4-oxadiazole. The compound is used to control nematodes in maize, soybeans, and cotton. It exhibits exceptional efficacy against lesion, root-knot, cyst, reniform, and needle nematodes. Tioxazafen is a valuable tool for agricultural pest management. |
| Molecular Formula |
C12H8N2OS
|
|---|---|
| Molecular Weight |
228.269721031189
|
| Exact Mass |
228.036
|
| CAS # |
330459-31-9
|
| PubChem CID |
695679
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
3.465
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
16
|
| Complexity |
233
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=C(C2=NOC(C3SC=CC=3)=N2)C=CC=C1
|
| InChi Key |
IHNSIFFSNUQGQN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H8N2OS/c1-2-5-9(6-3-1)11-13-12(15-14-11)10-7-4-8-16-10/h1-8H
|
| Chemical Name |
3-phenyl-5-thiophen-2-yl-1,2,4-oxadiazole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3808 mL | 21.9039 mL | 43.8078 mL | |
| 5 mM | 0.8762 mL | 4.3808 mL | 8.7616 mL | |
| 10 mM | 0.4381 mL | 2.1904 mL | 4.3808 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
